No Data
Express News | Relmada Therapeutics Inc: Files for Common Stock Offering of up to $100 Mln - SEC Filing
Relmada Therapeutics Price Target Announced at $8.00/Share by Leerink Partners
Relmada Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Leerink Partners Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $8
Relmada's New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline
Relmada Therapeutics Receives Written Feedback From FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ